Newsbenzinga
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
· Published
Article summary
OS Therapies reports a 72.7% three-year survival rate in its Phase 2b osteosarcoma trial, preparing for global regulatory submissions.
An excerpt from the original article.
Comments —
Loading comments…